Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-RT: Neoadjuvant Chemotherapy vs Chemoradiotherapy for Early Rectal Cancer
NCT06205485Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2024
- Primary completion
- Jan 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of folinic acid, oxaliplatin, fluorouracil, capecitabine in rectal cancer, sponsored by Canadian Cancer Trials Group. Started Jun 2024; status: recruiting.
02
Drugs
folinic acidoxaliplatinfluorouracilcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06205485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205485.